<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04369833</url>
  </required_header>
  <id_info>
    <org_study_id>H-2003-033-088</org_study_id>
    <nct_id>NCT04369833</nct_id>
  </id_info>
  <brief_title>Development of Continuous Glucose Monitoring System Cohort for Personalized Diabetes Prevention and Management Platform</brief_title>
  <official_title>Development of Continuous Glucose Monitoring System Cohort for Personalized Diabetes Prevention and Management Platform Based on Artificial Intelligence Model Using Mathematical Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pusan National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pusan National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect a variety of clinical data and blood glucose changes
      using a continuous glucose monitoring device for high-risk diabetes patients (prediabetes) in
      order to develop a personalized diabetes prevention and management platform based on
      artificial intelligence model using mathematical analysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed about the study and potential risks, all patients giving written
      informed consent wear a continuous glucose monitoring device (&quot;iPro2&quot; professional continuous
      glucose monitoring, MedtronicⓇ, California, USA) and smart band (&quot;Fitbit Inspire HR&quot;,
      FitbitⓇ, California, USA) for 1 week.

      During this period, all patients are tested oral glucose tolerance test and take a standard
      diet (calorie calculated) at morning.

      The patient's data from this study is compared to a predicted values by mathematical analysis
      model for diabetes prevention.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>7 Days</target_duration>
  <primary_outcome>
    <measure>Glucose/insulin levels pattern</measure>
    <time_frame>1 week</time_frame>
    <description>Explanatory power of multiple regression model of independent variables related to blood sugar / insulin (cycle, amplitude, mean and variance of blood sugar, mean and variance of insulin)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">130</enrollment>
  <condition>PreDiabetes</condition>
  <condition>Glucose Metabolism Disorders</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>continuous glucose monitoring group</arm_group_label>
    <description>all participants wearing a continuous glucose monitoring device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>continuous glucose monitoring system</intervention_name>
    <description>wearing continuous glucose monitoring device (iPro2 professional continuous glucose monitoring, MedtronicⓇ, California, USA)</description>
    <arm_group_label>continuous glucose monitoring group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood sample (for HbA1c, Total cholesterol, LDL-C, HDL-C, Triglyceride, aspartate
      aminotransferase, alanine aminotransferase, Creatinine, free fatty acid etc), Feces (for
      evaluating microbiomes)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects of pre-diabetes who visited the Department of Internal Medicine and division of
        Endodrinology &amp; Metabolism and the Health Examination Center, Pusan National University
        Hospital
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Above 18 years old.

          -  Prediabetes

               1. Fasting plasma glucose : 100~125mg/dL, fasting is defined as no caloric intake
                  for at least 8 hours.

                  OR

               2. 2-hour plasma glucose during 75g oral glucose tolerance test : 140 ~ 199mg/dL

                  OR

               3. Glycated hemoglobin(HbA1c) : 5.7~6.4% (39-47mmol/mol)

        Exclusion Criteria:

          -  with a history of newly diagnosed and treated cancer within the last 5 years

          -  with a history of hospitalization for active disease within the last 3 months

          -  with a history of severe cardiovascular disease within the last 3 months

          -  with a history of steroid treatment in the last 3 months

          -  people who have had major surgery planned within the last 3 months or who have had
             surgery within 3 months

          -  people who are pregnant or have been in the last 3 months after giving birth
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang soo Kim, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wook Yi, Bachelor</last_name>
    <phone>+82-51-240-7983</phone>
    <email>wg0405@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pusan national university hospital</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wook Yi, bachelor</last_name>
      <phone>+82-51-240-7983</phone>
      <email>wg0405@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Kang H, Han K, Jo J, Kim J, Choi MY. Systems of pancreatic beta-cells and glucose regulation. Front Biosci. 2008 May 1;13:6421-31. Review.</citation>
    <PMID>18508669</PMID>
  </results_reference>
  <results_reference>
    <citation>Hansen BC, Jen KC, Belbez Pek S, Wolfe RA. Rapid oscillations in plasma insulin, glucagon, and glucose in obese and normal weight humans. J Clin Endocrinol Metab. 1982 Apr;54(4):785-92.</citation>
    <PMID>7037815</PMID>
  </results_reference>
  <results_reference>
    <citation>Lang DA, Matthews DR, Peto J, Turner RC. Cyclic oscillations of basal plasma glucose and insulin concentrations in human beings. N Engl J Med. 1979 Nov 8;301(19):1023-7.</citation>
    <PMID>386121</PMID>
  </results_reference>
  <results_reference>
    <citation>Mendes-Soares H, Raveh-Sadka T, Azulay S, Edens K, Ben-Shlomo Y, Cohen Y, Ofek T, Bachrach D, Stevens J, Colibaseanu D, Segal L, Kashyap P, Nelson H. Assessment of a Personalized Approach to Predicting Postprandial Glycemic Responses to Food Among Individuals Without Diabetes. JAMA Netw Open. 2019 Feb 1;2(2):e188102. doi: 10.1001/jamanetworkopen.2018.8102.</citation>
    <PMID>30735238</PMID>
  </results_reference>
  <results_reference>
    <citation>Kim BY, Won JC, Lee JH, Kim HS, Park JH, Ha KH, Won KC, Kim DJ, Park KS. Diabetes Fact Sheets in Korea, 2018: An Appraisal of Current Status. Diabetes Metab J. 2019 Aug;43(4):487-494. doi: 10.4093/dmj.2019.0067. Epub 2019 Jul 17.</citation>
    <PMID>31339012</PMID>
  </results_reference>
  <results_reference>
    <citation>Ha KH, Lee YH, Song SO, Lee JW, Kim DW, Cho KH, Kim DJ. Development and Validation of the Korean Diabetes Risk Score: A 10-Year National Cohort Study. Diabetes Metab J. 2018 Oct;42(5):402-414. doi: 10.4093/dmj.2018.0014. Epub 2018 Jul 6.</citation>
    <PMID>30113144</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee YH, Bang H, Kim HC, Kim HM, Park SW, Kim DJ. A simple screening score for diabetes for the Korean population: development, validation, and comparison with other scores. Diabetes Care. 2012 Aug;35(8):1723-30. doi: 10.2337/dc11-2347. Epub 2012 Jun 11.</citation>
    <PMID>22688547</PMID>
  </results_reference>
  <results_reference>
    <citation>Zeevi D, Korem T, Zmora N, Israeli D, Rothschild D, Weinberger A, Ben-Yacov O, Lador D, Avnit-Sagi T, Lotan-Pompan M, Suez J, Mahdi JA, Matot E, Malka G, Kosower N, Rein M, Zilberman-Schapira G, Dohnalová L, Pevsner-Fischer M, Bikovsky R, Halpern Z, Elinav E, Segal E. Personalized Nutrition by Prediction of Glycemic Responses. Cell. 2015 Nov 19;163(5):1079-1094. doi: 10.1016/j.cell.2015.11.001.</citation>
    <PMID>26590418</PMID>
  </results_reference>
  <results_reference>
    <citation>Shapiro ET, Tillil H, Polonsky KS, Fang VS, Rubenstein AH, Van Cauter E. Oscillations in insulin secretion during constant glucose infusion in normal man: relationship to changes in plasma glucose. J Clin Endocrinol Metab. 1988 Aug;67(2):307-14.</citation>
    <PMID>3292558</PMID>
  </results_reference>
  <results_reference>
    <citation>Kraegen EW, Young JD, George EP, Lazarus L. Oscillations in blood glucose and insulin after oral glucose. Horm Metab Res. 1972 Nov;4(6):409-13.</citation>
    <PMID>4655495</PMID>
  </results_reference>
  <results_reference>
    <citation>Simon C, Brandenberger G, Follenius M. Ultradian oscillations of plasma glucose, insulin, and C-peptide in man during continuous enteral nutrition. J Clin Endocrinol Metab. 1987 Apr;64(4):669-74.</citation>
    <PMID>3102544</PMID>
  </results_reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The data are not publicly available due to privacy or ethical restrictions.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

